QR-Code

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Despite the role of epidermal growth factor receptor (EGFR) signaling in head and neck squamous cell carcinoma (HNSCC) development and progression, clinical trials involving EGFR tyrosine kinase inhibitors (TKIs) have yielded poor results in HNSCC patients. Mechanisms of acquired resistance to the E...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Aditya Stanam, Laurie Love-Homan, Tisha S. Joseph, Madelyn Espinosa-Cotton, Andrean L. Simons
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2015-08-01
Schriftenreihe:Molecular Oncology
Schlagworte:
HNSCC
EGFR
Erlotinib
Resistance
IL-6
Tocilizumab
Online-Zugang:https://doi.org/10.1016/j.molonc.2015.03.008
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge